CLN3
Basic information
Region (hg38): 16:28474111-28495575
Previous symbols: [ "BTS" ]
Links
Phenotypes
GenCC
Source:
- neuronal ceroid lipofuscinosis 3 (Definitive), mode of inheritance: AR
- neuronal ceroid lipofuscinosis 3 (Definitive), mode of inheritance: AR
- neuronal ceroid lipofuscinosis 3 (Strong), mode of inheritance: AR
- neuronal ceroid lipofuscinosis 3 (Definitive), mode of inheritance: AR
- neuronal ceroid lipofuscinosis 3 (Supportive), mode of inheritance: AR
- neuronal ceroid lipofuscinosis 3 (Strong), mode of inheritance: AR
- neuronal ceroid lipofuscinosis (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Ceroid lipofuscinosis, neuronal, 3 | AR | Neurologic | Levodopa treatment may be beneficial | Biochemical; Neurologic; Ophthalmologic | 7426545; 1609833; 1319116; 7553855; 7887420; 9004140; 9311735; 9450775; 10477428; 11342698; 15965709; 17947292; 19135632; 19489875; 21990111 |
ClinVar
This is a list of variants' phenotypes submitted to
- Neuronal ceroid lipofuscinosis (38 variants)
- Neuronal ceroid lipofuscinosis 3 (25 variants)
- not provided (11 variants)
- Retinitis pigmentosa (3 variants)
- Inborn genetic diseases (2 variants)
- Cone-rod dystrophy (2 variants)
- Ceroid lipofuscinosis, neuronal, 3, protracted (1 variants)
- early onset and severe retinal dystrophy (1 variants)
- Retinal dystrophy (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CLN3 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 210 | 213 | ||||
missense | 10 | 269 | 20 | 300 | ||
nonsense | 10 | 21 | 32 | |||
start loss | 3 | |||||
frameshift | 26 | 29 | 58 | |||
inframe indel | 5 | |||||
splice donor/acceptor (+/-2bp) | 41 | 49 | ||||
splice region | 1 | 4 | 22 | 65 | 5 | 97 |
non coding | 15 | 198 | 21 | 235 | ||
Total | 46 | 103 | 294 | 430 | 22 |
Highest pathogenic variant AF is 0.0000197
Variants in CLN3
This is a list of pathogenic ClinVar variants found in the CLN3 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
16-28477311-C-T | Neuronal Ceroid-Lipofuscinosis, Dominant/Recessive • Neuronal ceroid lipofuscinosis 3 | Uncertain significance (Jan 13, 2018) | ||
16-28477316-T-C | Neuronal Ceroid-Lipofuscinosis, Dominant/Recessive • Neuronal ceroid lipofuscinosis 3 | Uncertain significance (Jan 12, 2018) | ||
16-28477329-C-T | Neuronal ceroid lipofuscinosis 3 | Uncertain significance (Jan 12, 2018) | ||
16-28477361-T-G | Neuronal ceroid lipofuscinosis 3 | Likely benign (Jun 23, 2018) | ||
16-28477405-C-A | Neuronal ceroid lipofuscinosis 3 | Uncertain significance (Apr 27, 2017) | ||
16-28477417-G-A | Neuronal Ceroid-Lipofuscinosis, Dominant/Recessive • Neuronal ceroid lipofuscinosis 3 | Conflicting classifications of pathogenicity (Jul 08, 2018) | ||
16-28477438-C-T | Neuronal Ceroid-Lipofuscinosis, Dominant/Recessive • Neuronal ceroid lipofuscinosis 3 | Uncertain significance (Jan 13, 2018) | ||
16-28477458-T-G | Neuronal ceroid lipofuscinosis 3 | Uncertain significance (Mar 23, 2018) | ||
16-28477461-G-T | Neuronal Ceroid-Lipofuscinosis, Dominant/Recessive • Neuronal ceroid lipofuscinosis 3 | Uncertain significance (Jan 13, 2018) | ||
16-28477487-T-C | Neuronal Ceroid-Lipofuscinosis, Dominant/Recessive • Neuronal ceroid lipofuscinosis 3 | Uncertain significance (Jan 13, 2018) | ||
16-28477517-C-T | Neuronal ceroid lipofuscinosis | Likely benign (Mar 30, 2020) | ||
16-28477524-G-A | Uncertain significance (Apr 17, 2017) | |||
16-28477528-G-C | Neuronal ceroid lipofuscinosis • Inborn genetic diseases | Uncertain significance (Oct 25, 2022) | ||
16-28477531-G-T | Neuronal ceroid lipofuscinosis | Likely benign (Dec 20, 2022) | ||
16-28477540-A-G | Neuronal ceroid lipofuscinosis | Likely benign (May 02, 2023) | ||
16-28477542-G-A | Neuronal ceroid lipofuscinosis | Uncertain significance (Aug 28, 2021) | ||
16-28477545-G-A | Neuronal ceroid lipofuscinosis | Likely benign (Jan 29, 2024) | ||
16-28477548-G-A | Neuronal ceroid lipofuscinosis • Neuronal ceroid lipofuscinosis 3 | Uncertain significance (Aug 23, 2022) | ||
16-28477549-C-T | Neuronal ceroid lipofuscinosis | Likely benign (Dec 05, 2023) | ||
16-28477557-G-C | Neuronal ceroid lipofuscinosis | Uncertain significance (Sep 11, 2021) | ||
16-28477560-GC-G | Neuronal ceroid lipofuscinosis 3 | Likely pathogenic (-) | ||
16-28477561-C-T | Neuronal ceroid lipofuscinosis | Likely benign (Sep 17, 2020) | ||
16-28477564-C-T | Neuronal ceroid lipofuscinosis • Inborn genetic diseases | Likely benign (Dec 11, 2023) | ||
16-28477565-G-A | Retinitis pigmentosa • Neuronal ceroid lipofuscinosis | Uncertain significance (Sep 17, 2021) | ||
16-28477565-G-T | Neuronal ceroid lipofuscinosis 3 | Likely pathogenic (May 28, 2019) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CLN3 | protein_coding | protein_coding | ENST00000569430 | 15 | 28914 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.33e-7 | 0.951 | 125714 | 0 | 34 | 125748 | 0.000135 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.146 | 255 | 249 | 1.03 | 0.0000154 | 2766 |
Missense in Polyphen | 106 | 105.85 | 1.0015 | 1281 | ||
Synonymous | -1.08 | 129 | 114 | 1.13 | 0.00000767 | 946 |
Loss of Function | 1.93 | 15 | 25.5 | 0.588 | 0.00000122 | 283 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000578 | 0.0000578 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000218 | 0.000217 |
Finnish | 0.0000956 | 0.0000462 |
European (Non-Finnish) | 0.000205 | 0.000202 |
Middle Eastern | 0.000218 | 0.000217 |
South Asian | 0.000132 | 0.000131 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Involved in microtubule-dependent, anterograde transport of late endosomes and lysosomes. {ECO:0000269|PubMed:22261744}.;
- Disease
- DISEASE: Ceroid lipofuscinosis, neuronal, 3 (CLN3) [MIM:204200]: A form of neuronal ceroid lipofuscinosis. Neuronal ceroid lipofuscinoses are progressive neurodegenerative, lysosomal storage diseases characterized by intracellular accumulation of autofluorescent liposomal material, and clinically by seizures, dementia, visual loss, and/or cerebral atrophy. The hallmark of CLN3 is the ultrastructural pattern of lipopigment with a fingerprint profile, which can have 3 different appearances: pure within a lysosomal residual body; in conjunction with curvilinear or rectilinear profiles; and as a small component within large membrane-bound lysosomal vacuoles. The combination of fingerprint profiles within lysosomal vacuoles is a regular feature of blood lymphocytes from patients with neuronal ceroid lipofuscinosis type 3. {ECO:0000269|PubMed:21990111, ECO:0000269|PubMed:22261744, ECO:0000269|PubMed:9311735, ECO:0000269|PubMed:9490299}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Lysosome - Homo sapiens (human)
(Consensus)
Recessive Scores
- pRec
- 0.284
Intolerance Scores
- loftool
- 0.231
- rvis_EVS
- -0.16
- rvis_percentile_EVS
- 42.16
Haploinsufficiency Scores
- pHI
- 0.376
- hipred
- N
- hipred_score
- 0.146
- ghis
- 0.534
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.900
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Cln3
- Phenotype
- cellular phenotype; homeostasis/metabolism phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); vision/eye phenotype; immune system phenotype; renal/urinary system phenotype; liver/biliary system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype;
Zebrafish Information Network
- Gene name
- cln3
- Affected structure
- neuron
- Phenotype tag
- abnormal
- Phenotype quality
- morphology
Gene ontology
- Biological process
- action potential;globoside metabolic process;cellular amino acid metabolic process;ceramide metabolic process;glucosylceramide metabolic process;galactosylceramide metabolic process;sphingomyelin metabolic process;receptor-mediated endocytosis;lysosome organization;lysosomal lumen acidification;associative learning;arginine transport;macroautophagy;protein processing;protein catabolic process;ionotropic glutamate receptor signaling pathway;lysosomal lumen pH elevation;neurotransmitter metabolic process;amyloid precursor protein catabolic process;negative regulation of apoptotic process;negative regulation of catalytic activity;negative regulation of neuron apoptotic process;negative regulation of proteolysis;vesicle transport along microtubule;neuromuscular process controlling balance;regulation of intracellular pH;regulation of cytosolic calcium ion concentration;membrane organization;autophagosome maturation
- Cellular component
- Golgi membrane;nucleus;cytoplasm;mitochondrion;lysosome;lysosomal membrane;early endosome;late endosome;autophagosome;endoplasmic reticulum;Golgi apparatus;Golgi stack;trans-Golgi network;plasma membrane;caveola;synaptic vesicle;integral component of membrane;integral component of endoplasmic reticulum membrane;neuron projection;membrane raft
- Molecular function
- protein binding;unfolded protein binding